Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has provided an announcement.
On April 29, 2026, OKYO Pharma announced that senior executives will present new data and company developments at major ophthalmology meetings in Denver in early May. The events include CEO Robert J. Dempsey speaking at Eyecelerator on May 1, 2026, about unmet needs in corneal and anterior segment diseases, and CSO Raj Patil presenting Phase 2 first-in-human results for urcosimod in neuropathic corneal pain at the ARVO Annual Meeting on May 5, 2026.
The ARVO presentation will highlight clinically meaningful pain reduction and quality-of-life improvements in NCP patients treated with urcosimod, the first investigational therapy to receive an IND specifically for NCP and to secure FDA Fast Track designation for this indication. These appearances underscore OKYO’s bid to strengthen its profile in ocular pain and inflammation as it advances urcosimod toward a larger Phase 2b/3 trial in NCP and seeks to address a condition that currently lacks any FDA-approved targeted therapies.
The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, with its ordinary shares listed on the Nasdaq Capital Market. Its lead candidate, urcosimod, a chemerin peptide–based ChemR23 agonist, has shown anti-inflammatory and analgesic activity in preclinical models and achieved positive results in Phase 2 trials for both NCP and dry eye disease.
Average Trading Volume: 191,759
Technical Sentiment Signal: Sell
Current Market Cap: $81.16M
For an in-depth examination of OKYO stock, go to TipRanks’ Overview page.